HR 6222, the Justice for Victims of COVID Act, establishes a compensation program for families of U.S. citizens who died from COVID-19. It creates a fund financed by a 10% tariff on Chinese imports, which pays eligible survivors for out-of-pocket medical costs and up to $50,000 in lost wages. The program requires petitioners to prove COVID-19 was the primary cause of death, with payments distributed equally among surviving spouses, children, or parents. The bill also allows lawsuits against China for pandemic-related misrepresentations, creating a presumption that such statements caused harm. This applies solely to U.S. citizen deaths directly linked to the pandemic, with compensation limited to documented medical expenses and lost income.
The Maximum Pressure Act (HR 6114) is a legislative proposal that would maintain and expand U.S. sanctions against Iran. The bill would codify existing sanctions, require Iran to meet 12 specific conditions before sanctions could be lifted (including ending support for terrorism, releasing hostages, and ending nuclear enrichment), and expand sanctions on Iran's Revolutionary Guard Corps and missile programs. It also establishes new reporting requirements for the U.S. government to monitor Iran's activities and the impact of sanctions. The legislation would require congressional review before any sanctions could be lifted or modified, preventing the executive branch from unilaterally easing restrictions.
The PILLS Act creates tax credits to encourage domestic production of generic drugs and biosimilars. It provides a production credit (up to 35% of value added for final drug production) for manufacturers producing eligible drugs in the U.S., with additional bonus credits for domestically sourced materials. The bill also establishes a 25% investment credit for qualified facilities building new production capacity, with both credits phasing out after 2029 and terminating for new construction after 2027. These provisions directly affect U.S. pharmaceutical manufacturers of generic drugs and biosimilars, aiming to increase domestic supply of these medications.
This bill increases tariffs on ferrosilicon imported from Russia and Belarus to 35% of the product's value, targeting ferrosilicon classified under HTS code 7202.21.50. It requires the U.S. Trade Representative to assess within 30 days whether American producers can meet domestic demand if imports decline, with a public comment period on U.S. production capacity. If U.S. producers can scale up, the bill mandates notifying Congress and considering further tariff hikes. The authority to impose these tariffs is extended through 2025.
The DRA of 2023 adjusts Medicare payment rates for specific durable medical equipment (DME) items that were part of the 2021 competitive bidding program but for which no supplier contracts were finalized. It directly affects DME suppliers and Medicare beneficiaries by establishing a new 2024 payment formula: 90% of the adjusted payment amount plus 10% of the unadjusted fee schedule for eligible items. The bill also extends a temporary transition rule for non-rural areas through December 31, 2024, while delaying a regulatory change until 2025. These provisions aim to stabilize payments for DME items that did not transition to standard pricing under prior rules.
This bill clarifies that Medicare must cover external infusion pumps and associated non-self-administrable drugs as durable medical equipment (DME) when specific criteria are met. It directly affects Medicare beneficiaries requiring home infusion therapy for drugs that must be prepared just before use, administered by a healthcare professional, or labeled for external pump use at least monthly. Key provisions require the drug's FDA labeling to specify external pump administration, safe home delivery by qualified suppliers, and preparation/administration requirements. The bill mandates Medicare coverage under existing rules (LCD L33794) for qualifying treatments, effective upon enactment or FDA approval, whichever is later.
This bill expands Medicare benefits for chronic kidney disease patients by adding kidney disease screening to annual wellness visits and broadening education options to include more healthcare professionals like nurse practitioners. It updates payment systems to better cover innovative kidney treatments, including new drugs and devices, and requires a study on increasing kidney transplant rates. The bill also aims to improve the kidney care workforce by expanding training opportunities in underserved areas and ensures Medicare Advantage plans properly cover new kidney therapies. These changes directly affect Medicare beneficiaries with kidney disease, dialysis centers, and nephrology providers, with key provisions taking effect in 2022-2024.
The Clinical Laboratory Price Transparency Act of 2023 requires Medicare-participating laboratories to publicly disclose prices for specific clinical tests, including discounted cash prices and negotiated rates with health insurance plans. Starting January 1, 2025, labs must post this information on a standardized website (with annual updates) in a format established by the Department of Health and Human Services by 2028. Non-compliant labs face civil penalties of up to $300 per day after a 90-day correction period. This applies only to laboratories providing tests listed as "shoppable services" under Medicare (e.g., common blood or urine tests, excluding advanced diagnostic tests).
HR 4794, the Dietary Supplements Access Act, allows health savings accounts (HSAs), flexible spending accounts (FSAs), and health reimbursement arrangements (HRAs) to cover dietary supplements as qualified medical expenses. The bill amends the Internal Revenue Code to treat payments for dietary supplements - defined under federal law (21 U.S.C. 321(ff)) - as medical care, directly affecting individuals using these accounts to pay for supplements like vitamins or minerals. Key provisions require HSAs, FSAs, and HRAs to reimburse supplement costs under the same rules as other medical expenses. The change applies to taxable years beginning after the bill’s enactment.
HR 4673, the Ending Normal Trade Relations with China Act of 2023, would end the U.S. policy granting China lower tariffs on its exports. If enacted, it would require all Chinese-made goods to pay standard U.S. tariffs (the rates in column 2 of the Harmonized Tariff Schedule) starting two years after the law's passage, instead of the reduced "normal trade relations" rates. The bill also prevents future extension of this preferential status and allows the President to further increase tariffs on Chinese products. This change would directly affect Chinese exporters and U.S. importers of Chinese goods by raising their costs.
HR 4307, the Medical Supply Chain Resiliency Act, establishes a framework for the U.S. to negotiate agreements with trusted foreign partners to secure reliable supplies of critical medical goods like drugs and devices. It directs the President to create "trusted trade partner agreements" with countries that maintain open trade during health emergencies, protect intellectual property, and reduce unnecessary trade barriers. These agreements would eliminate duties or restrictions on medical goods, diversify supplier networks, and harmonize regulatory standards to prevent shortages like those seen during the pandemic. The bill directly affects U.S. manufacturers, healthcare providers, and importers by aiming to reduce over-reliance on a few nations for essential medical products.
HR 4073, the Duty Drawback Clarification Act, clarifies U.S. tariff classifications for imported whiskies by creating specific subheadings in the Harmonized Tariff Schedule. It replaces a single tariff line with eight new subheadings that categorize whiskies by type (Irish/Scotch, Bourbon, Rye, or "Other") and container size (under or over 4 liters), each with a uniform duty rate of $2.04 per liter. This change directly affects whiskey importers and manufacturers who must now classify products using these new codes when entering goods into U.S. commerce. The bill streamlines duty calculation and drawback claims (refunds of duties on imported goods later exported) by standardizing the tariff structure for whiskey categories.
